Immuneering to Present at the Jefferies Global Healthcare Conference
29 mai 2024 16h05 HE
|
Immuneering Corporation
Immuneering to Present at the Jefferies Global Healthcare Conference
[Latest] Global Non-Small-Cell Lung Cancer Drug Market Size/Share Worth USD 68,888.6 Million by 2033 at a 8.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
21 mai 2024 03h30 HE
|
Custom Market Insights
Austin, TX, USA, May 21, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Non-Small-Cell Lung Cancer Drug Market Size, Trends and Insights By Cancer Type...
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
07 mai 2024 16h05 HE
|
Immuneering Corporation
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
Immuneering Recognizes Melanoma Awareness Month
06 mai 2024 16h30 HE
|
Immuneering Corporation
Immuneering Recognizes Melanoma Awareness Month
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
17 avr. 2024 09h00 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, April 17, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
11 mars 2024 08h00 HE
|
Immuneering Corporation
- First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) - - Phase 2a portion of Phase...
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
06 mars 2024 07h30 HE
|
Kura Oncology, Inc.
– Company anticipates dosing of KO-2806 in combination with adagrasib in KRASG12C-mutant NSCLC next quarter – – Dose escalation of KO-2806 as a monotherapy continues in parallel – SAN DIEGO, March ...
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
05 mars 2024 16h30 HE
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
02 nov. 2023 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Blood Collection Devices Market Worth Nearly $14 Billion by 2030 - Exclusive Report by The Insight Partners
23 oct. 2023 09h35 HE
|
The Insight Partners
Pune, India, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Blood collection devices help in safe withdrawal of blood. Blood is collected from donor to perform various diagnostic tests. Needles & Syringes,...